First, the poly-agonist thesis has achieved sufficient validation that the competitive question is no longer whether multi-receptor approaches will succeed, but rather which specific receptor combinations and ratios will prove optimal for different patient populations
Recent phase 3 research involving oral semaglutide in early Alzheimers disease has also reinforced the need for caution: promising biology does not always translate into meaningful clinical benefit
GLP-1 drugs may reduce: Frequency of drinking Volume per occasion Desire to drink What this means across the three-tier system Suppliers Monitor changes in premium product demand Evaluate opportunities in lower-ABV and alternative beverages Distributors Watch for shifts in order frequency and product mix Identify regional differences tied to demographics and health trends Retailers On-premise: fewer drinks per visit Off-premise: smaller baskets and substitution effects Why this is a data problem If youre in beverage alcohol, this is a trend you wont see in your dashboardbut you will see it in your data
Meanwhile, they were significantly better than other GLP-1RAs in terms of efficacy
This substance works similarly to a naturally occurring hormone in the body called GLP-1, which is released from the intestines after eating
A GP can arrange basic investigations including a full blood count, thyroid function tests, and iron studies to exclude common treatable causes
